Treats hypertension. Sold as Sular. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Nisoldipine (sold as Sular), first approved Feb 2, 1995, with 0 new uses approved and 0 published complete response letters.
| Nisoldipine | Part D | $3.2M | -27% | 2,499 |
| Sular | Part D | $225K | -29% | 24 |
| Feb 2, 1995 | SularNDA 20356 · New molecular entity | Azurity | 17 | Marketed |
| Jul 25, 2008 | NisoldipineANDA 79051 | Mylan | 1 | Discontinued |
| Jan 26, 2011 | NisoldipineANDA 91001 | Mylan | 1 | Discontinued |
| Apr 10, 2023 | NisoldipineANDA 216606 | Amta | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Mylan